The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Rare Disease Genome Editing Market Change Between 2026 And 2030?
The rare disease genome editing market has shown rapid expansion in recent years. This market is set to grow from $1.29 billion in 2025 to $1.51 billion in 2026, with a compound annual growth rate (CAGR) of 17.8%. The historical growth can be attributed to several factors including advancements in gene editing technologies, a rising identification of rare genetic mutations, increased funding for genomic research, early successes observed in gene therapy trials, and growing academic research initiatives.
The rare disease genome editing market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $2.88 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.5%. This growth during the forecast period is fueled by several factors, including heightened investment in curative therapies for rare diseases, the increasing embrace of precision medicine strategies, an expansion of clinical trials in genome editing, stronger regulatory backing for orphan drugs, and greater cooperation between biotechnology firms and healthcare providers. Key developments throughout this period encompass the wider acceptance of CRISPR-based treatments, a heightened emphasis on gene editing for monogenic disorders, the expanding application of personalized genome editing techniques, the development of sophisticated editing platforms, and improved integration of genomic data analytics.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp
What Are The Main Drivers Accelerating The Growth Of The Rare Disease Genome Editing Market?
The expanding emphasis on precision medicine is anticipated to drive the advancement of the rare disease genome editing market in the future. Precision medicine, a customized healthcare strategy, utilizes a patient’s genetic makeup, surroundings, and lifestyle to deliver more precise and impactful therapies. The heightened attention on precision medicine stems from progress in genomic sequencing and biomarker identification, which facilitate accurate detection and specialized treatments. The rare disease genome editing market contributes to precision medicine by allowing for the specific correction of genetic mutations, thereby enhancing the personalization and efficacy of treatments. This approach improves healthcare by tackling the fundamental cause of rare disorders, leading to better patient results and less dependence on managing symptoms alone. For instance, Novotech, an Australia-based biotechnology company, reported in March 2024 that in 2023, precision oncology treatments accounted for 43% of the 217 FDA-approved oncology therapies, with 78 of these incorporating DNA or NGS-detectable biomarkers. Consequently, the growing emphasis on precision medicine is fostering the expansion of the rare disease genome editing market.
How Is The Rare Disease Genome Editing Market Distributed Across Key Segments?
The rare disease genome editing market covered in this report is segmented –
1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies
2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders
3) By Application: Therapeutics, Research
4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals
Subsegments:
1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing
2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases
3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)
4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases
Which Trends Are Guiding The Development Of The Rare Disease Genome Editing Market?
Leading companies within the rare disease genome editing market are concentrating on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, with the aim of enhancing treatment precision, improving patient outcomes, and addressing genetic diseases previously deemed incurable. CRISPR-based gene editing systems are innovative technologies that enable precise modifications to the genome, facilitating the correction of genetic defects or the introduction of therapeutic genes into cells. An illustrative case occurred in December 2023, when Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and secured conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is indicated for patients aged 12 and older who have sickle cell disease (SCD) with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy functions by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, which subsequently reduces or eliminates disease symptoms and offers a potential functional cure for these conditions.
Which Industry Players Are Present In The Rare Disease Genome Editing Market?
Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc
Access The Complete Rare Disease Genome Editing Market Report:
https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report
What Is The Largest Regional Market In The Rare Disease Genome Editing Market?
North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Rare Disease Genome Editing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp
Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company
Genome Editing Or Genome Engineering Market Report 2026
Crispr Gene Editing Market Report 2026
https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report
Gene Editing Market Report 2026
https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model